Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy by Erkan Topkan, Ahmet Kucuk, Duriye Ozturk, Emine Elif Ozkan, Ali Ayberk Besen, Berrin Pehlivan, Ugur Selek

“…We explored the prognostic utility of the unique combination of C-reactive-protein-to-albumin ratio (CAR) and significant weight loss (WL > 5%) over the preceding 6 months, namely, the CARWL score, in stage IIIC non-small-cell lung cancer (NSCLC) patients who underwent concurrent chemoradiotherapy (CCRT). …”
Get full text

Single‐cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers by Chenglin Yang, Jiahao Qu, Jingting Wu, Songhua Cai, Wenyi Liu, Youjun Deng, Yiran Meng, Liuqing Zheng, Lishen Zhang, Li Wang, Xiaotong Guo

“…However, the molecular mechanisms driving MPLCdevelopment and distinguishing it from solitary primary lung cancers (SPLCs)remain largely unexplored. Methods We performed a comparative single‐cell RNAsequencing (scRNA‐seq) analysis on tumour and adjacent para‐tumour tissues fromMPLC and SPLC patients to comparatively evaluate their immunological landscapes.Additionally, multiplex immunofluorescence (mIF) staining and independentvalidation datasets were used to confirm findings. …”
Get full text

Novel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency by Samaa Abdullah, Najla Altwaijry, Meaad Alnakhli, Ghezlan ALenezi, Alaa A. Al-Masud, Hanan Henidi, Yahya F. Jamous

Get full text

miR-224 activates cancer-associated fibroblasts to enhance lung cancer cell migration and invasion by targeting Akirin1 by Seonyeong Oh, Sieun Lee, Inyoung Cheon, Young-Ho Ahn

“…Furthermore, LFs overexpressing miR-224 enhanced the migration and invasion of lung cancer cells via direct cell-to-cell contact in a co-culture system. …”
Get full text

Smoking, DNA Adducts and Number of Risk DNA Repair Alleles in Lung Cancer Cases, in Subjects with Benign Lung Diseases and in Controls by Marco Peluso, Armelle Munnia, Sara Piro, Alessandra Armillis, Marcello Ceppi, Giuseppe Matullo, Riccardo Puntoni

“…Smoke constituents can induce DNA adducts that cause mutations and lead to lung cancer. We have analyzed DNA adducts and polymorphisms in two DNA repair genes, for example, XRCC1 Arg194Trp and Arg399Gln genes and XRCC3 Thr241Met gene, in 34 lung cancer cases in respect to 30 subjects with benign lung cancer disease and 40 healthy controls. …”
Get full text

An early lung cancer diagnosis model for non-smokers incorporating ct imaging analysis and circulating genetically abnormal cells (CACs) by Ran Ni, Yongjie Huang, Lei Wang, Hongjie Chen, Guorui Zhang, Yali Yu, Yinglan Kuang, Yuyan Tang, Xing Lu, Hong Liu

“…Abstract Background An increase in the prevalence of lung cancer that is not smoking-related has been noticed in recent years. …”
Get full text

Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China by Hua Zhong, Jun Lu, Mengzhao Wang, Baohui Han

“…The treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic therapy to the era of molecular biology-oriented targeted therapy and immunotherapy. …”

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer by Vesna Ćeriman Krstić, Dragana Jovanović, Natalija Samardžić, Milija Gajić, Jelena Kotur Stevuljević, Aleksandra Klisic, Ivan Soldatović, Damir Radončić, Marina Roksandić Milenković, Biljana Šeha, Nikola Čolić, Katarina Lukić, Milan Savić

“…Background/Objectives: A significant breakthrough in non-small-cell lung cancer (NSCLC) treatment has occurred with the introduction of targeted therapies and immunotherapy. …”
Get full text

Prognostic significance of pathological response and lymph node status in neoadjuvant immunotherapy for potentially resectable non-small cell lung cancer by Yuan Xu, Dongjie Ma, Yingzhi Qin, Hongsheng Liu

“…Objective To evaluate the predictive value of pathological response and lymph node status on progression-free survival (PFS) in patients with potentially resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant immunotherapy.Methods A retrospective analysis was conducted on 143 patients with potentially resectable NSCLC who underwent neoadjuvant immunotherapy followed by surgical resection. …”
Get full text

Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer by Jinbo Ma MD, Xiaoyan Ma MS, Wei Zhang MD, Shanliang Hu MS, Rukun Zang MS, Xiaolong Wu MS, Jie Song MD

“…Background Small cell lung cancer is sensitive to chemotherapy and radiotherapy, but local recurrence and distant metastasis occur shortly after treatment. …”
Get full text

FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway by Wen Meng, Jingfei Meng, Hong Jiang, Xing Feng, Dongshan Wei, Qingsong Ding

“…To study the expression, biological function, and mechanism of FKBP4 in non-small-cell lung cancer (NSCLC). Methods. First of all, the expression of FKBP4 in NSCLC tissues and cell lines was detected by qRT-PCR; then, the effects of FKBP4 on proliferation, apoptosis, migration, and invasion of NSCLC were studied by CCK-8 assays, flow cytometry assays, wound-healing assays, and Transwell assays. …”
Get full text

Ddx21 mutant peptide is an effective neoantigen in prophylactic lung cancer vaccines and activates long-term anti-tumor immunity by Zhe Zhang, Yimeng Xia, Yimeng Xia, Zhihong Wang, Yaxing Sun, Dan Pu, Yijia He, Ruixian Liu, Yanru Zhang, Yan Liu, Junzhi Yu, Shiyang Ning, Baisui Feng, Yaohe Wang, Na Wang

Subjects: “…lung cancer…”
Get full text

The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of lung cancer patients: a systematic review and meta-analysis by Xin Liu, Wu Lv, Danxue Huang, Hongxia Cui

Subjects: Get full text

Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy by Hohyung Nam, Soon‐Hee Jung, Jii Bum Lee, Jee Hyun Kong, Seungtaek Lim

“…ABSTRACT Introduction Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. …”
Get full text

YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer by Ling-Chen Li, Xie-Wan Chen, Ling Fang, Chun-Li Jian, Yong-Xin Yu, Xing-Yun Liao, Jian-Guo Sun

“…Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. …”
Get full text

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer by Carlos M Roggero, Anwesha B Ghosh, Anvita Devineni, Shihong Ma, Eliot Blatt, Ganesh V. Raj, Yi Yin

Subjects: Get full text

Circulating Tumor DNA Detection for Recurrence Monitoring of Stage I Non‐Small Cell Lung Cancer Treated With Microwave Ablation by Lin Cheng, Sheng Xu, Yu‐feng Wang, Sheng‐wei Li, Bin Li, Xiao‐Guang Li

“…ABSTRACT Purpose As microwave ablation continues to be used in patients with inoperable stage I non‐small cell lung cancer (NSCLC), it is particularly important to monitor efficacy. …”
Get full text

Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis by Preston Ngo, Wendy A. Cooper, Stephen Wade, Kwun M. Fong, Karen Canfell, Deme Karikios, Marianne Weber

Subjects: Get full text

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations by Abhimanyu Tushir, Israh Akhtar, Anjali Seth

Get full text

Comparative study of degree, neighborhood and reverse degree based indices for drugs used in lung cancer treatment through QSPR analysis by Micheal Arockiaraj, J. J. Jeni Godlin, S. Radha, Tariq Aziz, Mitub Al-harbi

“…This study focuses on the selection of drugs used to treat lung cancer, including dacomitinib, selpercatinib, tepotinib, trametinib, sotorasib, etoposide, alectinib, paclitaxel, dabrafenib, entrectinib, crizotinib, ceritinib, lorlatinib, afatinib, pralsetinib, brigatinib, erlotinib, adagrasib, gefitinib, vinorelbine, gemcitabine, docetaxel, and pemetrexed. …”
Get full text